Search

Rasem Mourad

Examiner (ID: 7274, Phone: (571)270-7770 , Office: P/2836 )

Most Active Art Unit
2836
Art Unit(s)
2836
Total Applications
617
Issued Applications
444
Pending Applications
46
Abandoned Applications
142

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 11403043 [patent_doc_number] => 20170023577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY' [patent_app_type] => utility [patent_app_number] => 15/080709 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56764 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15080709 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/080709
METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY Mar 24, 2016 Abandoned
Array ( [id] => 11090730 [patent_doc_number] => 20160287699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/079136 [patent_app_country] => US [patent_app_date] => 2016-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9847 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15079136 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/079136
FGFR/PD-1 combination therapy for the treatment of cancer Mar 23, 2016 Issued
Array ( [id] => 16954895 [patent_doc_number] => 11058722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain [patent_app_type] => utility [patent_app_number] => 15/560558 [patent_app_country] => US [patent_app_date] => 2016-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 13280 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560558 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/560558
Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain Mar 21, 2016 Issued
Array ( [id] => 16954895 [patent_doc_number] => 11058722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain [patent_app_type] => utility [patent_app_number] => 15/560558 [patent_app_country] => US [patent_app_date] => 2016-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 13280 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560558 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/560558
Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain Mar 21, 2016 Issued
Array ( [id] => 17586580 [patent_doc_number] => 11324822 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/559402 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12023 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559402 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/559402
Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer Mar 17, 2016 Issued
Array ( [id] => 12185493 [patent_doc_number] => 20180044429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'CD27 AGONISTS' [patent_app_type] => utility [patent_app_number] => 15/557035 [patent_app_country] => US [patent_app_date] => 2016-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 27358 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15557035 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/557035
CD27 AGONISTS Mar 8, 2016 Abandoned
Array ( [id] => 11948284 [patent_doc_number] => 20170252435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'Combination' [patent_app_type] => utility [patent_app_number] => 15/060071 [patent_app_country] => US [patent_app_date] => 2016-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 15107 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15060071 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/060071
Combination Mar 2, 2016 Abandoned
15/058286 ADOPTIVE T-CELL THERAPY USING FceRI-BASED CHIMERIC ANTIGEN RECEPTORS FOR TREATING IgE-MEDIATED ALLERGIC DISEASES Mar 1, 2016 Abandoned
Array ( [id] => 13793361 [patent_doc_number] => 20190010219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => Conditionally Active Chimeric Antigen Receptors for Modified T-Cells [patent_app_type] => utility [patent_app_number] => 15/753872 [patent_app_country] => US [patent_app_date] => 2016-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15753872 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/753872
Conditionally Active Chimeric Antigen Receptors for Modified T-Cells Feb 23, 2016 Abandoned
Array ( [id] => 10822106 [patent_doc_number] => 20160168270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID' [patent_app_type] => utility [patent_app_number] => 15/047612 [patent_app_country] => US [patent_app_date] => 2016-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 28219 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15047612 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/047612
PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID Feb 17, 2016 Abandoned
Array ( [id] => 16605980 [patent_doc_number] => 10906972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Cancer cell specific anti-podocalyxin antibody and method for producing same [patent_app_type] => utility [patent_app_number] => 15/549923 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 15391 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549923 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/549923
Cancer cell specific anti-podocalyxin antibody and method for producing same Feb 11, 2016 Issued
Array ( [id] => 10813744 [patent_doc_number] => 20160159904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'CANCER STEM CELL-SPECIFIC MOLECULE' [patent_app_type] => utility [patent_app_number] => 15/042548 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 74 [patent_figures_cnt] => 74 [patent_no_of_words] => 44171 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15042548 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/042548
Cancer stem cell-specific molecule Feb 11, 2016 Issued
Array ( [id] => 18604709 [patent_doc_number] => 11746159 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Humanized anti-MUC1* antibodies [patent_app_type] => utility [patent_app_number] => 15/549942 [patent_app_country] => US [patent_app_date] => 2016-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 62 [patent_no_of_words] => 33722 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549942 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/549942
Humanized anti-MUC1* antibodies Feb 9, 2016 Issued
Array ( [id] => 15696805 [patent_doc_number] => 10604570 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Chimeric antigen receptor signalling system comprising heterodimerization domains [patent_app_type] => utility [patent_app_number] => 15/548340 [patent_app_country] => US [patent_app_date] => 2016-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 13 [patent_no_of_words] => 10151 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15548340 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/548340
Chimeric antigen receptor signalling system comprising heterodimerization domains Feb 3, 2016 Issued
Array ( [id] => 12185488 [patent_doc_number] => 20180044424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/548202 [patent_app_country] => US [patent_app_date] => 2016-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 62 [patent_no_of_words] => 114282 [patent_no_of_claims] => 95 [patent_no_of_ind_claims] => 43 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15548202 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/548202
Car-expressing cells against multiple tumor antigens and uses thereof Jan 31, 2016 Issued
Array ( [id] => 13748791 [patent_doc_number] => 10167326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => Alpha-fetoprotein "ring and tail" peptides [patent_app_type] => utility [patent_app_number] => 15/010724 [patent_app_country] => US [patent_app_date] => 2016-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12753 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15010724 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/010724
Alpha-fetoprotein "ring and tail" peptides Jan 28, 2016 Issued
Array ( [id] => 12149990 [patent_doc_number] => 20180021253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 15/546852 [patent_app_country] => US [patent_app_date] => 2016-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 22301 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15546852 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/546852
Peritumoral and intratumoral materials for cancer therapy Jan 28, 2016 Issued
Array ( [id] => 10782952 [patent_doc_number] => 20160129109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 14/990514 [patent_app_country] => US [patent_app_date] => 2016-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10490 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14990514 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/990514
Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer Jan 6, 2016 Issued
Array ( [id] => 11066241 [patent_doc_number] => 20160263203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase' [patent_app_type] => utility [patent_app_number] => 14/984959 [patent_app_country] => US [patent_app_date] => 2015-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 103 [patent_figures_cnt] => 103 [patent_no_of_words] => 102982 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14984959 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/984959
Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase Dec 29, 2015 Abandoned
Array ( [id] => 11928682 [patent_doc_number] => 09795660 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-24 [patent_title] => 'Id-protein targeted tumor cell vaccine' [patent_app_type] => utility [patent_app_number] => 14/981114 [patent_app_country] => US [patent_app_date] => 2015-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 63 [patent_no_of_words] => 15152 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14981114 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/981114
Id-protein targeted tumor cell vaccine Dec 27, 2015 Issued
Menu